Navigation Links
Drug Firm Disowns Liability

The German biotech firm TeGenero, the drugs company behind the clinical trial listed its potential side effects on its 12-page document prepared by Parexel. //This consent form listed a side effect which can seriously harm the immune system. The clinical trial left six volunteers fighting for their lives. The consent form the men were asked to sign, which has been obtained by The Observer, warned that a possible effect of the drug was cytokine release. This includes a massive immune reaction to a chemical as it triggers an uncontrollable response from antibodies.

It is otherwise called as a cytokine release or cytokine storm. This can be life-threatening but the form does not spell that out. It is also doubtful whether the doctor heading the trial at Northwick Park Hospital in north London verbally highlighted the specific nature of the cytokine risk to the participants. The form says that that the drug could cause a hives-like allergic reaction. The volunteers were struck down with symptoms within minutes of being injected with the drug. A string of possible side effects are listed on the form, revealed for the first time in this newspaper. The consent form says that the participants may not experience any side effects as the doses used in early human studies are always very small.

But sometimes unintended effects may be encountered during any trial with a monoclonal antibody drug, though they did not occur even at the highest tested doses in animals. The various side effects listed are immunosuppression, autoimmunity, cytokine release, and anaphylaxis. Even the Medicines and Healthcare Products Regulatory Agency (MHRA) which authorised the trial was notified beforehand that there was this risk of cytokine release. The study obtained approval from German and UK authorities.


'"/>




Page: 1

Related medicine news :

1. Ex-workers Ask HLL to Accept Liability for Mercury Deaths
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: